" /> Livmoniplimab - CISMeF





Preferred Label : Livmoniplimab;

NCIt synonyms : Anti-glycoprotein A Repetitions Predominant Monoclonal Antibody ABBV-151; Anti-GARP Monoclonal Antibody ABBV-151;

NCIt definition : A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator, glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, livmoniplimab selectively targets and binds to GARP which interferes with the production and release of active TGFbeta by regulatory T-cells (Tregs). Selective inhibition of the release of TGFbeta from Tregs leads to a reversal of immunosuppression thereby increasing the immune response to tumor cells. GARP, a leucine-rich repeat-containing protein, is essential for the expression of TGFbeta on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function.;

UNII : 42SH7JCD82;

CAS number : 2412004-88-5;

Molecule name : ABBV 151; ARGX 115; ARGX-115; ABBV-151;

NCI Metathesaurus CUI : CL978918;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
08/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.